From GlobeNewswire: 2025-03-27 22:30:00

DBV Technologies secures financing of up to $306.9 million to advance Viaskin Peanut Patch through FDA submission and potential U.S. commercial launch. The funding includes $125.5 million up front and up to $181.4 million subject to warrant exercise. The VITESSE Phase 3 study hitting its primary endpoint will accelerate the exercise period of some warrants. The financing will result in an immediate dilution of 22.4% and up to 73.7% of existing shareholders if all warrants are exercised in full. The proceeds will be used for working capital, general corporate purposes, BLA preparation, and potential launch. The financing was led by various healthcare investors. The Company expects to extend its financial visibility into 2028 through potential commercialization of Viaskin Peanut in the U.S. DBV Technologies is a biopharmaceutical company developing treatment options for food allergies, focusing on Viaskin technology to address these conditions. The Company’s shares are traded on Euronext Paris and Nasdaq Capital Market. Forward-looking statements include the expected timing of closing the offering and use of proceeds, clinical trial results, regulatory submissions, and securities registration. The Company’s financial statements for 2024 will be published by April 15, 2025. The Offering is not subject to a prospectus requiring AMF approval. DBV Technologies will host an investor call on March 31, 2025, to discuss financing and FDA update. The securities offered are not registered under the Securities Act of 1933 and may not be sold in the U.S. without registration or exemption. The Offering does not constitute an offer in France, and in the EU, it is limited to qualified investors. In the UK, it is only directed at Relevant Persons. In the U.S., it is not an offer to sell or solicitation to buy securities.

Read more at GlobeNewswire: DBV Technologies Announces Financing of up to $306.9